XOMA Corp (NASDAQ:XOMA) — Market Cap & Net Worth
Market Cap & Net Worth: XOMA Corp (XOMA)
XOMA Corp (NASDAQ:XOMA) has a market capitalization of $339.92 Million ($339.92 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14434 globally and #3255 in its home market, demonstrating a 9.21% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying XOMA Corp's stock price $41.38 by its total outstanding shares 12383103 (12.38 Million). Analyse XOMA Corp (XOMA) cash conversion ratio to see how efficiently the company converts income to cash.
XOMA Corp Market Cap History: 2015 to 2026
XOMA Corp's market capitalization history from 2015 to 2026. Data shows growth from $329.39 Million to $512.41 Million (6.65% CAGR).
Index Memberships
XOMA Corp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #383 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1378 of 3165 |
Weight: XOMA Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
XOMA Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how XOMA Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
11.42x
XOMA Corp's market cap is 11.42 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $329.39 Million | $55.45 Million | -$20.61 Million | 5.94x | N/A |
| 2016 | $52.26 Million | $5.56 Million | -$53.53 Million | 9.39x | N/A |
| 2017 | $440.84 Million | $52.69 Million | $14.60 Million | 8.37x | 30.20x |
| 2018 | $156.65 Million | $5.30 Million | -$13.34 Million | 29.56x | N/A |
| 2019 | $338.06 Million | $18.37 Million | -$1.98 Million | 18.40x | N/A |
| 2020 | $546.47 Million | $29.39 Million | $13.30 Million | 18.60x | 41.09x |
| 2021 | $258.19 Million | $38.16 Million | $15.80 Million | 6.77x | 16.34x |
| 2022 | $227.85 Million | $6.03 Million | -$17.10 Million | 37.80x | N/A |
| 2023 | $229.09 Million | $4.76 Million | -$40.83 Million | 48.15x | N/A |
| 2024 | $325.43 Million | $28.49 Million | -$13.82 Million | 11.42x | N/A |
Competitor Companies of XOMA by Market Capitalization
Companies near XOMA Corp in the global market cap rankings as of May 4, 2026.
Key companies related to XOMA Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
XOMA Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, XOMA Corp's market cap moved from $329.39 Million to $ 512.41 Million, with a yearly change of 6.65%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $512.41 Million | +55.62% |
| 2025 | $329.27 Million | +1.18% |
| 2024 | $325.43 Million | +42.05% |
| 2023 | $229.09 Million | +0.54% |
| 2022 | $227.85 Million | -11.75% |
| 2021 | $258.19 Million | -52.75% |
| 2020 | $546.47 Million | +61.65% |
| 2019 | $338.06 Million | +115.81% |
| 2018 | $156.65 Million | -64.47% |
| 2017 | $440.84 Million | +743.60% |
| 2016 | $52.26 Million | -84.14% |
| 2015 | $329.39 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of XOMA Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $339.92 Million USD |
| MoneyControl | $339.92 Million USD |
| MarketWatch | $339.92 Million USD |
| marketcap.company | $339.92 Million USD |
| Reuters | $339.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About XOMA Corp
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential… Read more